- Jun 12, 2009
- Fellow [Any Field]
anybody have any local economic outcomes data on linezolid vs vanc in both skin and lung? all the data I can find is funded by pfizer. any insights about other data would be helpful. thanks
Oh, it's already underway but was wondering if folks had their own data/perspective. Ours of course is a retro look (chart review). What jumps out early is that our overall MRSA rate is down from 08-09, but virulence is up. MICs continue to trend up.I suggest you do your own retrospective study comparing Vanc vs. Linezolid in pneumonia and SSI at your facility and how the LOS was affected.
I say this because I think one of the main predictors of the outcome is the MRSA MIC and this is can vary greatly from institution to institution. Of course you need to evaluate the MIC methodology and the accurach.
what is making you want to try telavancin? I just wasn't impressed by the studies, and I feel like they are really glossing over the nephrotoxicity.I would be interested in seeing your results. I want to begin a retro study to see the same thing, although my only issue is now we are starting to try telavancin now, and lack of patients may make it a little difficult to see true rates. Anyways let us know if you find anything.
I did a small MUE on linezolid last year for other reasons and was not comparing to directly to Vanco. But some info you may find interesting.anybody have any local economic outcomes data on linezolid vs vanc in both skin and lung? all the data I can find is funded by pfizer. any insights about other data would be helpful. thanks